OBJECTiVES
The comprehensive economic costs of MS according to EDSS states can only be assessed by evaluating MS management in real clinical practice. The objective of this cross-sectional study was to measure resource utilisation and the costs associated with healthcare management of MS in Slovakia, and to provide a basis for cost-effectiveness evaluations.
RESulTS
According to the cross-sectional study results, 77% of patients had the relapsing-remitting form of MS (RRMS), which is the most common clinical form (80-85% in literature), characterized by acute attacks of certain CNS dysfunction followed by symptomatic remission (see figure 2) . The primary-progressive form (PPMS) is free from attacks, and occurs in about 10% of patients, mostly in men; 3% of patients in our study have this form of MS. 1% have the progressive-relapsing form (PRMS), which occurs generally in about 5% and is the most severe form, and leads to rapid disability. 19% of patients have the secondary-progressive form (SPMS), which according to literature occurs in approximately 30% of patients (14).
60% of patients had an EDSS score of 1-3, 34% of patients had an EDSS score of 4-6 and 6% had an EDSS score of 7-9 (see Figure 3 ).
The mean age of patients at the time of diagnosis was 32.3 years (± 9.7); 68% of patients were females and 32% were males (see Figure 4) . Disease modifying drugs (DMDs) have brought major changes in the management of MS therapies and in improving the clinical manifestations of MS. Immunomodulatory treatment is expensive and increases the cost of comprehensive treatment. 67% of patients in our study were receiving a 1 st line DMD, and 14% were receiving 2 nd line treatment. In the study cohort, DMDs were mostly applied in EDSS 2 (97%). The most frequently used DMDs were glatiramer acetate (20%), interferon beta-1a IM (15%), natalizumab (9%) and fingolimod (5%) (data shown in Figure 5 ).
Total direct health-care costs, DMDs excluded, ranged from € 752 for patients with an EDSS score of 1 to € 2,839 for patients with an EDSS score of 7. Costs for DMDs were from € 8,584 in patients with an EDSS score of 1 to € 13,026 patients with an EDSS score of 4 DMD costs were lower in patients with an EDSS score of 5 (€ 5,763) or EDSS 6 (€ 1,668); there were no associated DMD costs for patients with EDSS scores of 7-9, because of reimbursement restriction (data shown in Table 1 , Figure 6 ).
The most expensive grade 1/2 AEs were abdominal pain (€ 46.62), pain in joints, back and arms (€ 39.35).
METHODS
Thirty-four MS specialists across Slovakia were asked to participate in the study. The study had two e-forms: In Form A the structured descriptive epidemiological data registered in the MDs databases were collected (e.g. the total prevalent number of patients followed up in the centre according to the EDSS etc.). Form B consisted of patient case-lists and contained information from patients´ medical records. However, only 27 of the 34 MS specialists were able to complete Form A (structured epidemiological data), as the remaining 7 specialists had no possibility to extract the information from their databases. Descriptive epidemiological data of 2,552 MS patients from 27 MS specialists across Slovakia were collected electronically and analysed. In 152 selected patients followed up from 2011 to 2012 in MS centers and neurological clinics, all types of healthcare services and costs were analysed. These patients were randomly included in the study. Continuous variables were calculated using standard descriptive statistical methods. The cost-data were assessed for the year 2013. All types of healthcare used in MS management were evaluated (outpatient/inpatient visits, diagnostics, prescription drugs and medical examinations). Costs of adverse events (AEs) were set for the treatment of a single event. All healthcare costs were calculated per patient per year. The analysis was performed from the Slovak Health Insurance perspective, reflecting direct medical costs only. The structure of cost data follows the requirements of 
CONCluSiON
This cross-sectional study determined the average annual direct cost per MS patient to be € 1,640; DMDs excluded. DMD costs increase for patients with an EDSS score of 1 and peak costs at an EDSS score of 4, followed by a considerable decrease in DMD costs for EDSS scores of 5-6 and no DMD costs for EDSS scores of 7-9. As the EDSS score increase, the cost of medical devices rises. The estimate of of total costs through cost analysis of the disease allows for a realistic view of overall resource consumption associated with MS therapy in the Slovak healthcare system.
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